Trial Profile

A Pilot Study Assessing the Safety of Using a Monoclonal Antibody Against Cluster of Differentiation 40 (CD40) Ligand to Achieve a Calcineurin Inhibitor-free Immunosuppression Regimen in Patients With Type 1 Diabetes Mellitus (T1D) and Problematic Hypoglycemia Undergoing Islet Cell Transplantation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Basiliximab; Etanercept; Mycophenolate mofetil; Mycophenolate sodium
Indications Islet cell transplant rejection
Focus Therapeutic Use

14 May 2025 According to an Eledon Pharmaceuticals media release, updated interim clinical data anticipated late 2025.
20 Mar 2025 According to an Eledon Pharmaceuticals media release, interim clinical data expected in 2025.
13 Jan 2025 According to an Eledon Pharmaceuticals media release, longer-term follow up results from the study is expected in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com